Biocon Generics Inc. snaps up Eywa Pharma’s oral solid manufacturing site in the United States

INDIA – Biocon Generics Inc., a wholly-owned subsidiary of Biocon, has acquired Eywa Pharma Inc.’s oral solid dosage manufacturing facility in the United States in a deal valued at US$7.7 million (over Rs 63 crores).

As of September 1, 2023, Biocon Generics Inc. has full ownership of Eywa Pharma’s manufacturing facility located in New Jersey in the northeastern part of the United States.

The acquisition of the US FDA (US Food and Drug Administration) approved facility, marks the Indian biotechnology company’s first such site in the United States.

In a press release, Siddharth Mittal, Managing Director and Chief Executive Officer of Biocon, stated: “With this successful acquisition, our focus will be on integrating the acquired facility expeditiously and expanding our portfolio in the United States.”

Eywa Pharma’s existing workforce of the oral solid dose production facility is now part of the Biocon Generics Inc. team under the terms of the acquisition deal.

As part of the acquisition, the existing workforce of the US-based facility will transition into Biocon Generics Inc. in the coming weeks.

The oral solid dosage manufacturing facility has the potential for capacity expansion of up to 2 billion tablets/capsules per year.

Notably, the global oral solid dosage contract manufacturing market is estimated to be US$21 billion in 2023 and is anticipated to grow at a CAGR of approximately 5% during the forecast period.

Oral solid dosage formulations, including tablets, capsules, granules, sachets, powders, dry powder inhalers, and lozenges represent the most preferred dosage forms that are widely accepted by patients, worldwide.

Consequently, Biocon Generics Inc. will leverage the newly acquired manufacturing site to accelerate the supply and distribution of commercial formulations for oral solid dosages to its clients worldwide.

 “The acquisition of this US FDA-approved facility will complement Biocon’s existing manufacturing capabilities and strengthen our foothold in the US,” said Siddharth Mittal.

The acquisition will help the biotechnology company bolster its oral solid dosage capacities for new products ahead of schedule.

It not only aligns with the company’s outlined strategic objectives but also ensures continuity of supply through the diversification of manufacturing infrastructure.

In related news, Biocon’s biologics arm has finalized the integration of the acquired biosimilars business from Viatris in North America.

The integration of Viatris’ biosimilars business in North America will prove pivotal for Biocon Biologics as it further strengthens its leadership position in the global biosimilars industry.

It is in alignment with the company’s commitment to transforming healthcare and transforming lives by enabling affordable access to high-quality biosimilars for millions of patients worldwide.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.